NCT05175651View on ClinicalTrials.gov

Prospective Electronic Polygenic Risk Study - Second Phase

NANot yet recruitingINTERVENTIONAL
Enrollment

10,000

Participants

Timeline

Start Date

June 30, 2023

Primary Completion Date

January 15, 2025

Study Completion Date

January 15, 2027

Conditions
Coronary Artery DiseaseGlaucoma
Interventions
BEHAVIORAL

Genetic risk assessment

A coronary artery disease (CAD) and glaucoma polygenic risk scores (PRS) will be calculated for all study participants, with participants randomized to receiving either their CAD or glaucoma PRS.

Sponsors

Collaborators (1)

Illumina, Inc.
All Listed Sponsors
collaborator

Illumina, Inc.

INDUSTRY

collaborator

Optum, Inc.

INDUSTRY

collaborator

Quest Diagnostics-Nichols Insitute

INDUSTRY

lead

Scripps Translational Science Institute

OTHER